Mitochondrial Respiration in Intact Peripheral Blood Mononuclear Cells and Sirtuin 3 Activity in Patients with Movement Disorders

Figure 4

The mitochondrial respiration results and SIRT3 expression/activity in patients with movement disorders () with respect to treatment (1) and no treatment (0) using (a) levodopa (L-DOPA; A0, A1, ); (b) dopamine (DA) receptor agonists ropinirole and pramipexole (B0, ; B1, ); (c) selegiline (C0, ; C1, ); (d) rasagiline (D0, ; D1, ); and (e) amantadine (E0, ; E1, ). The results are expressed as median (interquartile range).

(a)

(b)

(c)

(d)

(e)